Cargando…

Clinical predictors of treatment efficacy and a prognostic nomogram in patients with lung adenocarcinoma receiving immune checkpoint inhibitors: a retrospective study

BACKGROUND: At present, there is no accurate biomarker for immune checkpoint inhibitors (ICIs). Since the efficacy of ICIs is associated with a variety of indicators, establishing a model to predict its efficacy is more clinically significant and in line with clinical needs. METHODS: We collected an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Fang, Peng, Jin, Niu, Yanjie, Mao, Xiaowei, Zhao, Yizhuo, Jiang, Liyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9641362/ https://www.ncbi.nlm.nih.gov/pubmed/36389292 http://dx.doi.org/10.21037/jtd-22-1270

Ejemplares similares

Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors
por: Chen, Xiuqiong, et al.
Publicado: (2022)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Serum NSE is Early Marker of Transformed Neuroendocrine Tumor After EGFR-TKI Treatment of Lung Adenocarcinoma
por: Mao, Xiaowei, et al.
Publicado: (2022)

Using T stage and tumor thrombosis as predictive factors for patients with resected I–IIA small cell lung cancer: a retrospective study
por: Mao, Xiaowei, et al.
Publicado: (2021)

tsRNA-5001a promotes proliferation of lung adenocarcinoma cells and is associated with postoperative recurrence in lung adenocarcinoma patients
por: Hu, Fang, et al.
Publicado: (2021)

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
por: Zheng, Fei, et al.
Publicado: (2023)

New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors
por: Lin, Xuwen, et al.
Publicado: (2023)

Is there a progression‐free survival benefit of first‐line crizotinib versus standard chemotherapy and second‐line crizotinib in ALK‐positive advanced lung adenocarcinoma? A retrospective study of Chinese patients
por: Cui, Shaohua, et al.
Publicado: (2016)

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Pietrantonio, Filippo, et al.
Publicado: (2021)

Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
por: Yan, Xuebing, et al.
Publicado: (2023)

ENPEP as a potential predictor of immune checkpoint inhibitor efficacy
por: Wang, Aoyun, et al.
Publicado: (2021)

The Clinical Value of Pulmonary Rehabilitation in Reducing Postoperative Complications and Mortality of Lung Cancer Resection: A Systematic Review and Meta-Analysis
por: Mao, Xiaowei, et al.
Publicado: (2021)

Characteristics and Prognostic Nomogram for Primary Lung Lepidic Adenocarcinoma
por: Tang, Hui, et al.
Publicado: (2022)

Receptor–ligand pair typing and prognostic risk model of response or resistance to immune checkpoint inhibitors in lung adenocarcinoma
por: Mao, Shengqiang, et al.
Publicado: (2023)

The Feasibility and Safety of Surgery in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study
por: Elias, Alexandra W., et al.
Publicado: (2017)

Nomogram for predicting the survival of gastric adenocarcinoma patients who receive surgery and chemotherapy
por: Wang, Chao-Yang, et al.
Publicado: (2020)

Reduced FEV(1) as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
por: Shen, Yi-Luen, et al.
Publicado: (2022)

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia
por: Li, Xiaoqi, et al.
Publicado: (2022)

Prognostic analysis and nomogram establishment in patients with early esophageal cancer receiving endoscopic therapy: a population-based study
por: Sun, Danping, et al.
Publicado: (2023)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

Development and validation of prognostic nomograms for patients with metastatic small bowel adenocarcinoma: a retrospective cohort study
por: Zhu, Hanlong, et al.
Publicado: (2022)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Development and validation of a prognostic nomogram for gallbladder papillary adenocarcinoma
por: Wang, Zhenfeng, et al.
Publicado: (2023)

B Cell Receptor Signaling Pathway Mutation as Prognosis Predictor of Immune Checkpoint Inhibitors in Lung Adenocarcinoma by Bioinformatic Analysis
por: Lin, Anqi, et al.
Publicado: (2022)

Prognostic effect of cachexia in patients with non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Matsuo, Norikazu, et al.
Publicado: (2023)

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors
por: Liu, Chunxun, et al.
Publicado: (2023)

The Prognostic Significance of Nomogram-Based Pretreatment Inflammatory Indicators in Patients With Esophageal Squamous Cell Carcinoma Receiving Intensity-Modulated Radiotherapy
por: Xu, Zhiyang, et al.
Publicado: (2023)

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment
por: Lin, Anqi, et al.
Publicado: (2022)

EFNA3 as a predictor of clinical prognosis and immune checkpoint therapy efficacy in patients with lung adenocarcinoma
por: Deng, Mingming, et al.
Publicado: (2021)

A Prognostic Nomogram for Hepatocellular Carcinoma Based on Wound Healing and Immune Checkpoint Genes
por: Hu, Beiyuan, et al.
Publicado: (2022)

Efficacy and predictors of rechallenge with immune checkpoint inhibitors in non‐small cell lung cancer
por: Takahara, Yutaka, et al.
Publicado: (2022)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

Development and Validation of a Clinical Prognostic Nomogram for Esophageal Adenocarcinoma Patients
por: Shao, Chen-ye, et al.
Publicado: (2021)

Prognostic Nomogram for patients undergoing radical Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head
por: Wu, Chao, et al.
Publicado: (2021)

Development and validation of a prognostic nomogram for extrahepatic bile duct adenocarcinoma
por: Zhang, Shiyao, et al.
Publicado: (2022)

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
por: Lopez-Olivo, Maria A., et al.
Publicado: (2022)

Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors
por: Kelly, Deirdre, et al.
Publicado: (2021)

Prognostic nutritional index for predicting the clinical outcomes of patients with gastric cancer who received immune checkpoint inhibitors
por: Sun, Hao, et al.
Publicado: (2022)

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
por: Yi, Ming, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6u20i9niokkbtt3ggb0qok8q3i